Opus Genetics will present the full clinical dataset and additional analyses evaluating key measures of visual function at upcoming leading ophthalmology meetings including Euretina Innovation Spotlight (EIS), Euretina 2026, Retina in Rio, and FLORetina.
Published
Signal category
Presence & Recognition
Quote
“The full clinical dataset and additional analyses evaluating key measures of visual function will also be presented at several upcoming leading ophthalmology meetings:”
— Opus Genetics team
Company
Opus Genetics
Gene therapy company for inherited retinal diseases
- Industry
- Biotechnology Research
- Location
- Raleigh, US
- Company size
- 46 employees
Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders. The Company’s pipeline features AAV-based gene therapies targeting inherited retinal diseases including Leber congenital amaurosis (LCA), bestrophinopathy, and retinitis pigmentosa. Its lead gene therapy candidates are OPGx-LCA5, which is in an ongoing Phase 1/2 trial for LCA5-related mutations, and OPGx-BEST1, a gene therapy targeting BEST1-related retinal degeneration. Opus Genetics is also advancing Phentolamine Ophthalmic Solution 0.75%, a partnered therapy currently approved in one indication and being studied in two Phase 3 programs for presbyopia and reduced low light vision and nighttime visual disturbances.